发明名称 |
USE OF FGFR1 EXTRA CELLULAR DOMAIN PROTEINS TO TREAT CANCERS CHARACTERIZED BY LIGAND-DEPENDENT ACTIVATING MUTATIONS IN FGFR2 |
摘要 |
The present invention relates to the use of Fibroblast Growth Factor Receptor I (FGFR1) extracellular domain (ECD) polypeptides for treatment of cancers characterized by ligand dependent activating mutations in Fibroblast Growth Factor Receptor 2 (FGFR2). For example, the present invention relates to the treatment of endometrial cancers and other cancers wherein tumor cells express FGFR2 mutants in the IgII-IgIII hinge region or IgIII domain of the protein, such as at amino acid positions 252 and/or 253. |
申请公布号 |
US2014227263(A1) |
申请公布日期 |
2014.08.14 |
申请号 |
US201314079742 |
申请日期 |
2013.11.14 |
申请人 |
Five Prime Pharmaceuticals, Inc. |
发明人 |
Harding Thomas;Kavanaugh W. Michael |
分类号 |
C07K14/71 |
主分类号 |
C07K14/71 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method of treating a cancer characterized by a ligand dependent activating mutation in FGFR2 in a subject, comprising administering a therapeutically effective amount of an FGFR1 ECD to the subject. |
地址 |
South San Francisco CA US |